Patent Issued for Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use (USPTO 11975063).

A patent has been issued for a recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) that expresses the respiratory syncytial virus (RSV) G protein. RSV is a common cause of bronchiolitis and pneumonia in infants, and there is currently no effective vaccine. The rB/HPIV3 vectors described in the patent are infectious, attenuated, and self-replicating, and they have the potential to induce an immune response to both RSV and HPIV3. This patent provides a potential avenue for the development of a safe and effective immunogen for RSV and HPIV3, particularly in pediatric subjects. [Extracted from the article]